Found: 17
Select item for more details and to access through your institution.
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs.
- Published in:
- International Immunology, 2007, v. 19, n. 10, p. 1223, doi. 10.1093/intimm/dxm091
- By:
- Publication type:
- Article
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
- Published in:
- Annals of the New York Academy of Sciences, 2013, v. 1291, n. 1, p. 1, doi. 10.1111/nyas.12180
- By:
- Publication type:
- Article
A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection
- Published in:
- PLoS ONE, 2013, v. 8, n. 5, p. 1, doi. 10.1371/journal.pone.0063818
- By:
- Publication type:
- Article
Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy.
- Published in:
- Nature Communications, 2019, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41467-019-11719-3
- By:
- Publication type:
- Article
Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis.
- Published in:
- Critical Care, 2013, v. 17, n. 3, p. 1, doi. 10.1186/cc12711
- By:
- Publication type:
- Article
Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis.
- Published in:
- 2013
- By:
- Publication type:
- journal article
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target.
- Published in:
- 2020
- By:
- Publication type:
- journal article
TIGIT and PD-1 impair tumor antigen-specific CD8<sup>+</sup> T cells in melanoma patients.
- Published in:
- Journal of Clinical Investigation, 2015, v. 125, n. 5, p. 2046, doi. 10.1172/JCI80445
- By:
- Publication type:
- Article
TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
- Published in:
- 2015
- By:
- Publication type:
- journal article
The Human Vaccines Project: A roadmap for cancer vaccine development.
- Published in:
- Science Translational Medicine, 2016, v. 8, n. 334, p. 1, doi. 10.1126/scitranslmed.aaf0685
- By:
- Publication type:
- Article
TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection.
- Published in:
- PLoS Pathogens, 2016, v. 12, n. 1, p. 1, doi. 10.1371/journal.ppat.1005349
- By:
- Publication type:
- Article
Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
- Published in:
- 2016
- By:
- Publication type:
- Correction Notice
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
- Published in:
- PLoS ONE, 2016, v. 11, n. 9, p. 1, doi. 10.1371/journal.pone.0161779
- By:
- Publication type:
- Article
An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients.
- Published in:
- PLoS ONE, 2018, v. 13, n. 6, p. 1, doi. 10.1371/journal.pone.0198158
- By:
- Publication type:
- Article
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Author Correction: Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Author Correction: Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice